Ir para o conteúdo principal

Vera Therapeutics (NYSE: VERA) — Perfil da empresa, notícias e dados financeiros

Logo de Vera Therapeutics
VERA Vera Therapeutics
Vera Therapeutics primary media
Perfil da empresa

Vera Therapeutics

Vera Therapeutics (NASDAQ:VERA) is a biotechnology company focused on advancing treatments for serious immunological diseases. Their operations are concentrated on developing and commercializing novel therapies aimed at improving the lives of patients battling conditions where current treatments fall short. A key project in their pipeline is the pursuit of innovative solutions for kidney diseases, with a strong emphasis on precision medicine to tailor treatments to individual patient needs. Vera Therapeutics is dedicated to pushing the boundaries of science to discover and develop therapies that can make a significant difference in patient care. Their objective is to lead with science-driven approaches, ensuring that their developments not only address unmet medical needs but also offer improved outcomes for patients worldwide.

Resumo

Public USParticipação acionária
2016Ano de fundação
61Funcionários
California, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
United States

Produtos e/ou serviços de Vera Therapeutics

  • Atacicept, a fusion protein aimed at treating IgA nephropathy by inhibiting APRIL and BLyS molecules implicated in B cell maturation.
  • MAU868, a monoclonal antibody for combating BK virus in kidney transplant patients.
  • Research in chronic autoimmune and inflammatory diseases, focusing on identifying novel treatments.
  • Collaborations with pharmaceutical companies to develop and commercialize innovative therapies.
  • Patient support programs designed to assist with access to treatments and managing chronic diseases.
  • Investment in advanced technologies for drug development and delivery systems.

equipe executiva do Vera Therapeutics

  • Marshall W. FordyceFounder, President, CEO & Director
  • Sean P. GrantChief Financial Officer
  • David L. JohnsonChief Opearating Officer
  • Robert M. BrennerChief Medical Officer
  • Joseph R. YoungSenior VP of Finance & Chief Accounting Officer
  • S. Sandra ParkSenior VP of Legal, Healthcare,Commercial Law, Compliance & Operations
  • Jane Wright-MitchellChief Legal Officer & Secretary
  • Debra CharlesworthVice President of Corporate Communications
  • Emma HaywoodVice President of Marketing
  • Tom DoanExecutive Vice President of Development Operations

Principais indicadores financeiros

Resultados divulgados pela Vera Therapeutics, em USD.

Cap. de mercado
2,2 bi
Receita (TTM)
0
P/L
—
LPA (diluído, TTM)
-5.5
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da Vera Therapeutics
Fim do ano fiscalReceitaResultado operacionalLucro líquido
0-315,5 mi-299,6 mi
0-167,2 mi-152,1 mi
1,9 mi-102 mi-96 mi
0-90,9 mi-89,1 mi